Skip to content

"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514942-35-00
Acronym
1509-0003
Enrollment
9
Registered
2025-03-07
Start date
2025-04-11
Completion date
Unknown
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 interferonopathies

Interventions

None listed

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium, France, Germany, Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026